Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
2/27/24 Minerva Neurosciences (NERV) MIN-101 (Minerva) for Schizophrenia Subscribers Only Subscribers Only Subscribers Only
2/27/24 Viking (VKTX) VK2735 for Obesity Subscribers Only Subscribers Only Subscribers Only
2/26/24 ARS Pharmaceuticals (SPRY) Neffy for Urticaria Subscribers Only Subscribers Only Subscribers Only
2/26/24 Boehringer Ingelheim Survodutide for Non-Alcoholic Steatohepatitis (NASH) Subscribers Only Subscribers Only Subscribers Only
2/26/24 GSK (GSK) GSK2140944 for Urinary Tract and Reproductive Tract Infections (Antibacterial) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
02/16/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
02/16/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
02/29/24 Subscribers Only Subscribers Only Regulatory - NDA/BLA Filing
02/29/24 Subscribers Only Subscribers Only Partnership - Acquisition Completion
02/29/24 Subscribers Only Subscribers Only Regulatory - Other